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Summary
Hermansky-Pudlak syndrome (HPS) consists of ocu-
locutaneous albinism, a platelet storage-pool deficiency,
and ceroid lipofuscinosis. In a recent report on the
cloning of anHPS gene, all 22 Puerto RicanHPS patients
were homozygous for a 16-bp duplication in exon 15.
This presumably reflected a founder effect for the HPS
mutation in Puerto Rico. Nevertheless, we ascertained
two individuals from central Puerto Rico who lacked
the 16-bp duplication, exhibited significant amounts of
normal-size HPS mRNA by northern blot analysis, and
had haplotypes in the HPS region that were different
from the haplotype of every 16-bp–duplication patient.
Moreover, these two individuals displayed no mutations
in their cDNA sequences, throughout the entire HPS
gene. Both patients exhibited pigment dilution, impaired
visual acuity, nystagmus, a bleeding diathesis, and absent
platelet dense bodies, confirming the diagnosis of HPS.
These findings indicate that analysis of Puerto Rican
patients for the 16-bp duplication inHPS cannot exclude
the diagnosis of HPS. In addition, HPS most likely
displays locus heterogeneity, consistent with the
existence of several mouse strains manifesting both
pigment dilution and a platelet storage-pool deficiency.
Introduction
Hermansky-Pudlak syndrome (HPS) consists of the triad
of oculocutaneous albinism, a bleeding diathesis, and
lysosomal accumulation of ceroid lipofuscin (Herman-
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sky and Pudlak 1959). The sine qua non for diagnosis
of this autosomal recessive disorder is the absence of
platelet dense bodies on wet-mount electron microscopy
(Witkop et al. 1987a); this finding explains the lack of
a secondary aggregation response of platelets in vitro,
as well as easy bruisability in patients themselves. The
albinism of HPS manifests with congenital nystagmus,
iris transillumination, a visual acuity range of 20/50–20/
400, and variable reductions in skin pigmentation (Sum-
mers et al. 1988; Witkop et al. 1989). Ceroid lipofuscin
consists of an unidentified lipid/protein complex consid-
ered to accumulate in cellular lysosomes and to cause
pulmonary fibrosis (Garay et al. 1979; Harmon et al.
1994) and granulomatous colitis (Schinella et al. 1980)
in some patients. HPS reportedly occurs in 1/1,800 peo-
ple in northwestern Puerto Rico (Witkop et al. 1990),
because of a founder effect, but it has also been described
in a Swiss isolate (Lattion et al. 1983) and in almost all
ethnic groups (Witkop et al. 1989). In addition, several
inbred strains of mice have both pigment dilution and
a platelet storage-pool defect (Novak et al. 1984). Two
genes responsible for these mouse phenotypes, ruby eye
and pale ear (Novak et al. 1981), map to mouse chro-
mosome 19, in a region syntenic with human chromo-
some 10q23, the location of the human HPS gene. Re-
cently, the pale ear gene was shown to be homologous
to the human HPS gene (Feng et al. 1997; Gardner et
al. 1997).
The genetic mapping of HPS, performed by linkage
analysis in 36 families from northwestern Puerto Rico
(Wildenberg et al. 1995), permitted subsequent physical
mapping of HPS (Oh et al. 1996). Cloning and cDNA
sequencing demonstrated that the gene’s coding region
contains 2,100 bp, predicting a protein with a presumed
molecular weight of 79.3 kD. Although 20 exons are
now known to exist, and although the genomic structure
of HPS has been described (Bailin et al. 1997), the func-
tion of the HPS product remains unknown. In the orig-
inal report on theHPS gene (Oh et al. 1996), mutational
analysis revealed a homozygous, 1-bp insertion at codon
P324 in six Swiss patients and one Irish patient and a
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Table 1
PCR Primer Sets for Amplifying cDNA Fragments of HPS
Fragment Primer Sequences Nucleotidesa
HP-1 (310 bp) 5′-GCTTGCCAAGATGAAGTGCGTC-3′ 9 to 12
5′-TCGGTGTGGTCACCATTGATG-3′ 300 to 279
HP-2 (401 bp) 5′-GGAGAATGCCTGTTCATTGCC-3′ 259 to 279
5′-AATGCCAGCAGCTTGGAGTG-3′ 659 to 640
HP-3 (437 bp) 5′ CCAAGCTGCTGGCATTCTACTC-3′ 644 to 665
5′-GCTTTCCTTCACGTTGGCATC-3′ 1080 to 1060
HP-4 (357 bp) 5′-ACACCCTCCAAACACTGGTTCC-3′ 998 to 1019
5′ TAAACTCCAGCCAGGTGCTCTG-3′ 1354 to 1333
HP-5 (405 bp) 5′-TTGTCAAGAATCGAGGGGCAC-3′ 1304 to 1324
5′-CCAACTCCGACGAGGTCTTTTG-3′ 1708 to 1687
HP-6 (415 bp) 5′-CGGCTGAACTTTCTGACCACAG-3′ 1447 to 1468
5′-ACCCCATGTCATTCTCGAACC-3′ 1861 to 1841
HP-7 (338 bp) 5′-CCTACTTCCTGTGGTCGAGAATG-3′ 1829 to 1852
5′-GAACAGTGGCAAGCAAGGGTG-3′ 2166 to 2146
a Nucleotide numbering is according to standard nomenclature, with the A of the ATG
initiation codon assigned the numeral “1.” Note that this is nucleotide number 207 in the
numbering system of Oh et al. (1996).
homozygous, 1-bp insertion at codon A441 in a single
inbred Japanese patient. All 22 Puerto Rican HPS pa-
tients examined were homozygous for the same muta-
tion, a 16-bp duplication in exon 15 of HPS (Oh et al.
1996). This finding, combined with the strong popula-
tion evidence of a founder effect, raised the possibility
that all Puerto Rican HPS patients could be diagnosed
with a simple molecular test based on PCR amplification
of the region encompassing the 16-bp duplication.
However, we have ascertained two individuals of
Puerto Rican ancestry who display the clinical charac-
teristics of HPS yet lack the 16-bp duplication. In fact,
they exhibit no discernible mutation in HPS, suggesting
that locus heterogeneity has resulted in two types of
HPS, arising in different geographical areas of Puerto
Rico.
Subjects and Methods
All patients were enrolled in a protocol approved by
the National Institute of Child Health and Human De-
velopment institutional review board, to study the clin-
ical, biochemical, and molecular aspects of HPS. In-
formed consent was obtained either from each patient
or from the patient’s parents.
Electron Microscopy of Platelet Dense Bodies
Fresh blood was immediately mixed in a 9:1 ratiowith
93.0 mmol sodium citrate/liter, 7.0 mmol citric acid/liter,
and 140 mmol dextrose/liter (pH 6.5). Drops of platelet-
rich plasma, separated from whole cells by centrifuga-
tion at 100 g for 20 min at room temperature, were
placed on the top sides of formvar-coated, carbon-sta-
bilized 300-mesh copper grids for 10–15 s. The grids
were rinsed sequentially with four drops of distilled wa-
ter, with care not to wet the bottom sides. The first three
drops were shaken off immediately, and the fourth was
quickly removed from the edges with filter paper. Grids
were air-dried and were examined in a Phillips Model
301 electron microscope.
PCR Detection of the 16-bp Duplication
DNA was prepared from peripheral blood lympho-
cytes (Sambrook et al. 1989). A 269-bp fragment span-
ning exon 15 of HPS was amplified by PCR in a 50-ml
volume containing 50 mM KCl, 1.5 mM MgCl2, 5 mM
Tris (pH 8.3), 200 mM dNTPs, 0.01% gelatin, 0.6 mM
primers (5′-GATGGTCCACAAAGGACGAG-3′/5′-GC-
GTGAAGGAAGTACGGGCC-3′), 2.5 U Taq polymer-
ase, and 500 ng template DNA. After an initial dena-
turation step at 94C for 2 min, PCR was conducted for
30 cycles, each consisting of a 1-min denaturation step
at 94C, followed by annealing for 30 s at 60C, and
extension for 1 min at 72C, and a final elongation step
for 10 min at 72C. PCR products were electrophoresed
in 3% agarose and were stained with ethidium bromide.
SSCP Analysis
Fibroblast RNA was reverse transcribed by use of a
first-strand cDNA kit (Gibco-BRL), and the 2.1-kb cod-
ing region of the HPS cDNA was amplified by use of
seven sets of primers (table 1). The PCR was performed
with 50 mM KCl, 1.5 mM MgCl2, 5 mM Tris (pH 8.3),
200 mM dNTPs, 0.01% gelatin, 2.5 U Taq polymerase,
0.4 mM each primer, and 2 ml cDNA, in a final volume
of 50 ml. Products were radiolabeled by inclusion of 1
mCi a-32P[dCTP]. After an initial denaturation step at
94C for 3 min, PCR was conducted for 30 cycles, each
with a denaturation step at 94C for 30 s, annealing at
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56C for 30 s, and extension at 72C for 2 min, and a
final elongation step at 72C for 10 min. The PCR prod-
ucts were denatured with 10 ml formamide and heating
at 94C for 10 min and were fractionated, either at room
temperature or at 4C, by electrophoresis for 12 h on a
0.5#MDE gel (AT Biochemical). The gel was prepared
in 0.6# Tris-borate EDTA with or without 5% glycerol
and was subjected to autoradiography.
Sequence Analysis
Direct, automated fluorescent sequencing was per-
formed, by Biotech Research Laboratories, on cDNA
fragments of HPS that had been PCR-amplified by use
of the primers listed in table 1. Additional sequencing
was performed on full-length cDNA that was PCR-am-
plified by use of the HP-1 forward primer and the HP-
7 reverse primer. After being subcloned into the pCR
2.1 vector (InVitrogen), several clones were selected, and
two clones representing different alleles were chosen by
identification of specific polymorphic sequences. DNA
sequencing was performed by use of an ABI 373 auto-
mated DNA sequencer, according to a standard protocol
supplied by the manufacturer (Perkin-Elmer). Both
strands of DNA were sequenced.
Northern Blots
Total RNA (10 mg), isolated from cultured fibroblasts
by use of Trizol reagent (Life Technologies), was sepa-
rated on a 1.2% agarose/3% formaldehyde gel and was
blotted onto a Nytran nylon membrane (Schleicher &
Schuell) in the presence of 20 # SSC. The blot was
prehybridized and then hybridized with ExpressHyb so-
lution (Clontech) at 68C. Full-length human HPS
cDNA, random primer labeled with a-32P[dCTP]
(duPont/NEN), served as the probe. After hybridization,
the blot was washed several times at room temperature
with 2 # SSC/0.05% SDS and once with 0.1 # SSC/
0.1% SDS at 50C and was exposed to Kodak XAR film
with an intensifying screen for 24 h at 70C.
Haplotype Analysis
Simple tandem-repeat polymorphisms were amplified
in 5-ml PCR reactions (Wildenberg et al. 1995) contain-
ing the two primers specific to the marker and a third,
fluorescently labeled primer that hybridizes to a 19-bp
tail added to the 5′ end of one of the marker primers
(5′-CACGACGTTGTAAAACGAC-3′). Reactions were
prepared in 96-well plates with 2 mM MgCl2, 50 mM
KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton-X-100,
200 mM dNTPs, 1 pmol each marker primer, 0.1 pmol
M13 primer, 1 U Taq polymerase, and 20 ng DNA. PCR
products were separated on a 5.5% denaturing acrylam-
ide gel by use of the LI-COR DNA 4000 automated
infrared sequencer (LI-COR). Allele sizes were deter-
mined by use of RFLPScan software (Scanalytics).
Results
Case Reports
Patient 1 is a 47-year-old man born in New York City
of parents who both came from Naranjito, Puerto Rico.
He had nystagmus at birth, and his hair color was lighter
than that of three siblings but was the same shade as
that of two other siblings. These two siblings have not
been extensively investigated and have not been diag-
nosed with HPS. The patient had worn glasses since 2–3
years of age. Bruising had occurred since the time of
ambulation, and nosebleeds had been frequent in ele-
mentary school. Rectal bleeding at age 5 years had re-
quired a transfusion, and surgeries for tonsillectomy,
strabismus repair, and intestinal blockage had caused
excessive bleeding. Aggregation studies performed at age
44 years had resulted in the diagnosis of HPS, and the
patient had been treated prophylactically with desmo-
pressin acetate for subsequent hernia repairs. During the
past 3 years, bloody stools have occurred occasionally
but have been attributed to anal fissures. The patient
now experiences dyspnea after walking either three
blocks or up one flight of stairs.
On physical examination, height was 170 cm, weight
was 113.6 kg, and skin pigmentation appeared normal
(fig. 1B). Best corrected visual acuity was 20/50 in the
right eye and 20/100 in the presumably amblyopic left
eye, with significant horizontal nystagmus and minimal
transillumination (fig. 1B). Unlike other albino patients,
this man exhibited hypopigmentation in the periphery
of the retina and choroid, with prominent choroidal vas-
culature in the posterior pole. The hemoglobin was 15.1
g/dl, with a hematocrit of 45% and a platelet count of
287,000/mm3. Electron microscopy of a wet mount of
platelets showed absent dense bodies (fig. 2B). Total se-
rum cholesterol was 221 mg/dl, with LDL-cholesterol of
136 mg/dl and HDL-cholesterol of 35 mg/dl. Triglyc-
erides were 252 mg/dl. On pulmonary function testing,
the forced vital capacity was 85% of predicted, forced
expiratory in 1 s was 94% of predicted, total lung ca-
pacity was 83% of predicted, and diffusing capacity for
carbon monoxide was 101% of predicted. A computed-
tomography scan of the chest revealed no fibrosis. Serum
electrolytes, liver-function tests, mineral levels, and thy-
roid studies were normal. The serum creatinine was 1.0
mg/dl, and two 24-h urine creatinine-clearance values
were 141 and 125 ml/min.
Patient 2 is a 4-year 11-mo–old girl from Philadelphia.
Her maternal grandmother was from Arecibo, Puerto
Rico, her paternal grandmother and grandfather were
from Aibonito, Puerto Rico, and her maternal grand-
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Figure 1 Pigment dilution in Puerto Rican patients with HPS. A patient homozygous for the 16-bp duplication in exon 15 of HPS has
light eyebrows and eyelashes, with extensive iris transillumination (A), whereas, in contrast, patient 1 has significant hair pigmentation and
negligible iris transillumination (B), and patient 2 has relatively dark hair and moderate iris transillumination (C).
Figure 2 Electron micrograph of wet mount of platelets from a normal individual (A), patient 1 (B), and patient 2 (C) (#9,700). Patients
1 and 2 lack platelet dense bodies.
father was from Naranjito, Puerto Rico. The only rel-
evant family history was that the father’s paternal uncle
had light skin and bruising but no visual impairment or
nystagmus. At birth, the patient herself had nystagmus
and blond hair, which later darkened; she was diagnosed
with albinism at 2 mo of age. She began bruising on
ambulation at 10–12 mo of age but did not experience
nosebleeds or excessive bleeding on cutting her skin.
Platelet-aggregation studies at 3 years of age led to the
diagnosis of HPS.
On physical examination, height was 107 cm (40th
percentile), and weight was 19.3 kg (75th percentile).
Her skin was mildly depigmented (fig. 1C). Visual acuity
was 20/100 in each eye, but its reliability was question-
able, in view of the patient’s age. Iris transillumination
was moderate (fig. 1C). Fundus examination revealed
significant hypopigmentation of the retina and choroid.
Laboratory studies revealed a hemoglobin level of 11.7
g/dl, hematocrit of 35%, and platelet count of 319,000/
mm3. Electron microscopy of a wet mount of platelets
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Figure 3 Agarose gel electrophoresis of HPS fragment contain-
ing 16-bp duplication in exon 15. PCR fragments were amplified from
the genomic DNA of two normal individuals (lanes 1 and 6), two
classic Puerto Rican HPS patients (lanes 2 and 5), and our patients 1
and 2 (lanes 3 and 4). DNA size markers are on the right. The normal-
size fragment is 269 bp; the 285-bp fragment reflects a 16-bp dupli-
cation. A 3% agarose gel was employed.
Figure 4 Northern blot ofHPSmRNA. Total RNA fromnormal
kidney (lane 1), normal fibroblasts (lane 2), fibroblasts carrying the
16-bp duplication in HPS (lanes 3 and 4), and fibroblasts of patient
2 (lane 5) and of patient 1 (lane 6) were probed with the full-length
HPS cDNA. Probing with b-actin indicates unequal loading, but lane
1 serves as a normal control for lane 6, and lane 2 provides a control
for lane 5. Patients homozygous for the 16-bp duplication exhibited
no HPS mRNA, whereas patients 1 and 2 displayed significant
amounts of normal-size HPS mRNA.
showed absent dense bodies (fig. 2C). Pulmonary-func-
tion tests were poorly performed. The serum creatinine
was 0.6 mg/dl, and electrolytes, liver-function tests, min-
eral levels, and thyroid studies were all normal.
Molecular Studies
PCR amplification in the region of exon 15 of HPS
revealed the typical 16-bp duplication, yielding a 285-
bp product, in 25/27 Puerto Rican patients. All these
patients or their parents were originally from north-
western Puerto Rico, and all were homozygous for the
16-bp duplication. In contrast, patients 1 and 2 dis-
played a normal-size, 269-bp fragment (fig. 3), with no
evidence of the 285-bp fragment. Consequently, a mu-
tation in HPS was sought by performance of SSCP anal-
ysis of the two patients’ cDNA. This was accomplished
by PCR amplification of HPS cDNA in seven separate
fragments (table 1). Only fragment 6 in patient 1 and
fragments 5 and 6 in patient 2 showed a difference from
normal migration on an MDE gel (data not shown).
Sequencing demonstrated that the fragment 5 change
occurred because patient 2 was heterozygous for
c1472CrG, a known polymorphism causing a P491R
alteration (Oh et al. 1996). The fragment 6 changes re-
flected the finding that patient 1 was homozygous and
patient 2 was heterozygous for c1809GrA, resulting in
an R603Q change. This alteration is also a nonpath-
ologic polymorphism (Bailin et al. 1997) and corre-
sponds to the normal sequence of the mouse ep gene,
the homologue of the human HPS (Feng et al. 1997;
Gardner et al. 1997). Subsequently, all seven HPS frag-
ments were subjected to direct sequencing, and full-
length HPS cDNA clones representing both alleles of
each patient were also sequenced. Normal sequence was
observed in the area of the 16-bp duplication, for all
four alleles of patients 1 and 2. No amino acid–altering
changes were observed in any other region of HPS.
HPS expression was assessed in patients 1 and 2 by
northern blot analysis of RNA extracted from their cul-
tured fibroblasts. The RNA filter, which also contained
samples from normal individuals and from Puerto Rican
patients harboring the 16-bp duplication, was probed
with the full-length HPS cDNA. Although patients ho-
mozygous for the 16-bp duplication showed no HPS
RNA, patients 1 and 2 displayed an approximately nor-
mal contingent of normal-size HPS RNA (fig. 4).
Haplotype Analysis
Typical Puerto Rican HPS patients exhibit a particular
haplotype in the area surrounding the HPS gene (Wil-
denberg et al. 1995). In fact, their homozygosity at three
specific loci on chromosome 10q2 (D10S58, D10S184,
and D10S1433) reflects the founder effect for this au-
tosomal recessive disease. Using markers for five loci
surrounding HPS, we found that patients 1 and 2 ex-
hibited, at each of the five loci, at least one allele that
differed from that of the 16-bp–duplication patients (ta-
ble 2). This meant that our two patients expressed four
unique haplotypes, none of which was shared by the
Puerto Rican patients homozygous for the 16-bp
duplication.
Discussion
In clinical practice, HPS is diagnosed on the basis of
the presence of albinism and a platelet storage-pool de-
fect. Ceroid lipofuscin appears only sporadically among
non–Puerto Ricans with HPS (Witkop et al. 1987b) and
accumulates gradually even in Puerto Rican patients
with classic HPS. Hence, our patients 1 and 2 fulfill
standard criteria for HPS. They exhibit skin-pigment di-
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Figure 5 Map of Puerto Rico. Patients with the 16-bp dupli-
cation are from northwestern Puerto Rico (shaded). Our two patients
have ancestors in Naranjito and Aibonito.
Table 2
Haplotypes and Alleles in the Region of HPS, for Puerto Rican
Patients with HPS
LOCUS
HAPLOTYPES OF
PATIENTS WITH
16-BP
DUPLICATION
ALLELESa
Patient 1 Patient 2
D10S577 214 214 202, 206 206, 202
D10S58 226 226 222, 240 240, 222
D10S184 174 174 176, 184 174, 182
D10S1433 204 204 220, 220 216, 224
D10S198 201 201 201, 187 201, 187
a Family studies to determine haplotypes were not performed.
lution, relative to other family members, as well as iris
transillumination, nystagmus, and impaired visual acu-
ity. In each case, a clinical bleeding diathesis suggested
the diagnosis of HPS, which was confirmed by aggre-
gation studies and by the absence of platelet dense bodies
on electron microscopy (fig. 2).
Nevertheless, our patients did not display the exact
HPS phenotype characteristic of Puerto Rican patients.
Visual-acuity deficits were less severe than those of clas-
sically affected patients. Our patients manifested mini-
mal or moderate iris transillumination, compared with
other Puerto Rican HPS patients, and their skin was only
mildly depigmented (fig. 1). Indeed, molecular analysis
confirmed that patients 1 and 2 are neither homozygous
nor heterozygous for the 16-bp duplication that char-
acterizes typical Puerto Rican HPS. This was demon-
strated by PCR amplification (fig. 3) and direct sequenc-
ing of the region. Furthermore, cultured fibroblasts of
patients 1 and 2 exhibited substantial amounts of nor-
mal-size HPS mRNA, which was absent from cells of
patients homozygous for the 16-bp duplication (fig. 4).
Finally, our two patients together displayed four differ-
ent haplotypes in the region of HPS, none of which was
the haplotype found in every patient bearing the 16-bp
duplication (table 2).
If our atypical HPS patients did not manifest the 16-
bp duplication, did they have a mutation elsewhere in
HPS? Extensive direct and clonal sequencing of the en-
tire HPS cDNA of both patients revealed only two poly-
morphisms, P491R (Oh et al. 1996) and R603Q (Bailin
et al. 1997). The genomic DNA corresponding to a
short, 1.5-kb alternate transcript of HPS was also se-
quenced in patients 1 and 2, and no mutation was found
(S. Wildenberg, personal communication).
The absence of a disease-causing mutation in theHPS
genes of our two patients suggests that HPS can be
caused by mutations at another locus. It would not be
surprising for other human loci to produce the cardinal
features of HPS, since mutations in at least 12 different
mouse loci give rise to the combination of pigment di-
lution and a storage-pool defect (Novak et al. 1981,
1984). There may even be a second founder effect for
HPS on the island of Puerto Rico. The towns of origin
of the two atypical patients—the towns of Naranjito and
Aibonito—are ∼12 miles apart in central Puerto Rico,
10 miles from San Juan but 40–70 miles from north-
western Puerto Rico (fig. 5). Patients fromNaranjito and
Aibonito would not have been included in mapping
(Wildenberg et al. 1995) and cloning (Oh et al. 1996)
studies involving excursions only to northwestern Puerto
Rican cities such as Arecibo, Camuy, Hatillo,Queradilla,
Aguadilla, and Moca. In our investigations, this bias of
ascertainment was eliminated by acquisition of Puerto
Rican patients from the mainland United States whose
region of origin was unknown at the time of recruitment.
Even though patients 1 and 2 are clearly not homozy-
gous for any haplotype in the area ofHPS (table 2), they
may be homozygous for haplotypes surrounding another
locus, and this would support a separate founder effect.
Patients 1 and 2 demonstrate that the diagnosis of
HPS homozygosity or heterozygosity cannot be excluded
in Puerto Rican individuals simply by the demonstration
of the absence of the 16-bp duplication in exon 15 of
HPS. However, since all 25 of our patients from north-
western Puerto Rico were homozygous for the 16-bp
duplication, screening of patients from this part of the
island may be useful. Our patients expand the phenotype
of Puerto Rican HPS, to include a milder degree of hair,
skin, and iris hypopigmentation and a milder visual def-
icit; these findings may help to differentiate this variant
phenotype from the classic Puerto Rican disorder. More
patients must be followed in order to determine the ex-
tent of pulmonary and gastrointestinal involvement in
the new phenotype.
Finally, locus heterogeneity, if proved, should prompt
the genetics community to decide what constitutes HPS.
Is it a clinical diagnosis requiring the presence of albi-
nism and a bleeding diathesis (with or without ceroid
lipofuscinosis), or is it a molecular diagnosis requiring
the presence of a mutation in the one known HPS gene?
This situation for HPS resembles that for Zellweger dis-
ease 10 years ago, when a farrago of peroxisomal dis-
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orders was under investigation, each entity acquiring, in
turn, definition as a specific defect (Lazarow and Moser
1995). For HPS, such resolution should arrive in the
next few years, as mutations in the known HPS gene
and in other causative loci are delineated and as their
phenotypes are reported in detail.
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